NHAS
VERV

Novo Holdings A/S’s Verve Therapeutics VERV Stock Holding History

Novo Holdings A/S’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,000,000
Closed -$13.7M – 33
2025
Q1 		$13.7M Buy
3,000,000
+600,000
+25% +$4.02M 1.04% 22
2024
Q4 		$13.5M Hold
2,400,000
– – 0.82% 24
2024
Q3 		$11.6M Hold
2,400,000
– – 0.58% 29
2024
Q2 		$11.7M Buy
2,400,000
+400,000
+20% +$2.51M 0.63% 32
2024
Q1 		$26.6M Hold
2,000,000
– – 1.83% 21
2023
Q4 		$27.9M Buy
+2,000,000
New +$24.8M 1.72% 23
2023
Q3 		– Sell
-500,000
Closed -$9.38M – 41
2023
Q2 		$9.38M Sell
500,000
-700,000
-58% -$11.7M 0.72% 32
2023
Q1 		$17.3M Buy
1,200,000
+288,889
+32% +$5.66M 1.14% 26
2022
Q4 		$17.6M Hold
911,111
– – 1.1% 23
2022
Q3 		$31.3M Sell
911,111
-15,989
-2% -$510K 1.49% 17
2022
Q2 		$14.2M Buy
927,100
+177,100
+24% +$2.74M 0.7% 28
2022
Q1 		$17.1M Buy
750,000
+50,000
+7% +$1.43M 0.9% 20
2021
Q4 		$25.8M Buy
700,000
+100,000
+17% +$4.2M 1.22% 17
2021
Q3 		$28.2M Sell
600,000
-193,265
-24% -$11.4M 1.46% 15
2021
Q2 		$47.8M Buy
+793,265
New +$32.9M 2.12% 14

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Novo Holdings A/S's VERV Position: Q2 2025 in Review

Novo Holdings A/S sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 3,000,000 shares — an estimated $13.7M sold.

Novo Holdings A/S first reported a position in VERV in Q2 2021 and held it in 15 quarters. The position peaked at $47.8M in Q2 2021. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Novo Holdings A/S reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Novo Holdings A/S sold 3,000,000 Verve Therapeutics shares in Q2 2025, an estimated $13.7M.
  • Novo Holdings A/S first reported a position in Verve Therapeutics in Q2 2021 and held it in 15 quarters.
  • Novo Holdings A/S's Verve Therapeutics position peaked at $47.8M in Q2 2021.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Novo Holdings A/S's 13F filing for Q2 2025, filed 14 Aug 2025.